Genprex (NASDAQ:GNPX) Trading Down 11.2% – Here’s Why

Posted by Stephan Jacobs on Apr 22nd, 2026

Genprex (NASDAQ:GNPX – Get Free Report)’s share price traded down 11.2% on Monday . The stock traded as low as $1.15 and last traded at $1.1550. 985,204 shares were traded during mid-day trading, an increase of 193% from the average session volume of 336,366 shares. The stock had previously closed at $1.30.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Check Out Our Latest Research Report on Genprex

Genprex Stock Down 6.4%

The company has a market capitalization of $9.22 million, a price-to-earnings ratio of -0.04 and a beta of -0.69. The stock has a 50 day simple moving average of $1.75 and a 200 day simple moving average of $3.81.

Institutional Investors Weigh In On Genprex

An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP grew its position in shares of Genprex (NASDAQ:GNPX – Free Report) by 11.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 340,056 shares of the company’s stock after acquiring an additional 35,661 shares during the quarter. Susquehanna International Group LLP owned about 27.20% of Genprex worth $58,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 14.05% of the company’s stock.

About Genprex

(Get Free Report)

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.